Quantum Biopharma (NASDAQ:QNTM – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday.
Separately, Weiss Ratings lowered shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.
View Our Latest Analysis on QNTM
Quantum Biopharma Stock Performance
Hedge Funds Weigh In On Quantum Biopharma
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in Quantum Biopharma during the 4th quarter worth about $76,000. Jane Street Group LLC purchased a new stake in Quantum Biopharma during the 4th quarter valued at about $80,000. Finally, Platform Technology Partners acquired a new position in shares of Quantum Biopharma in the first quarter valued at about $199,000. Hedge funds and other institutional investors own 1.24% of the company’s stock.
Quantum Biopharma Company Profile
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.
Recommended Stories
- Five stocks we like better than Quantum Biopharma
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Quantum Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
